• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Español
  • English
  • Bloglovin
  • Email
  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
CDE Almería – Centro de Documentación Europea – Universidad de Almería

CDE Almería - Centro de Documentación Europea - Universidad de Almería

Centro de Documentación Europea de la Universidad de Almería

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact

EMA preparing guidance to tackle COVID-19 variants

Inicio » EU News » Health » Diseases » EMA preparing guidance to tackle COVID-19 variants

16/02/2021

EMA is developing guidance for manufacturers planning changes to the existing COVID-19 vaccines to tackle the new virus variants. In order to consider options for additional testing and development of vaccines that are effective against new virus mutations, the Agency has requested all vaccine developers to investigate if their vaccine can offer protection against any new variants, e.g. those identified in the United Kingdom, South Africa and Brazil, and submit relevant data.

EMA preparing guidance to tackle COVID-19 variants

EMA will shortly publish a reflection paper that will set out the data and studies needed to support adaptations of the existing vaccines to current or future mutations of SARS-CoV-2 in the European Union (EU). The questions that will be addressed as part of this reflection paper include:

  • Which are the options for introducing a new strain into an existing approved vaccine?
  • What will be the minimal regulatory requirements to demonstrate the quality, safety and efficacy?
  • Which bridging studies will be required to provide adequate reassurance of a vaccine’s efficacy against a new strain, either as first vaccination or as booster

EMA has authorised three vaccines for use in the EU: Comirnaty, COVID-19 Vaccine Moderna, and COVID-19 Vaccine AstraZeneca. There are concerns that some of these mutations could impact to different degrees the ability of the vaccines to protect against infection and disease. A reduction in protection from mild disease would however not necessarily translate into a reduction in protection from serious forms of the disease and its complications, for which we need to collect more evidence.

Typically, viruses mutate when the genetic material in the virus changes. This happens at different rates for different viruses and mutations do not necessarily affect how well a vaccine works against the virus. Some vaccines against viral diseases remain effective many years after their development and provide long-lasting protection, such as vaccines for measles or rubella. On the other hand, for diseases such as flu, the vaccine composition needs to be updated on a yearly basis for it to be effective, because the virus mutates and renders previous immunity ineffective.

COVID-19 variants have been present since March 2020, steadily spreading even before the start of the vaccination campaigns. EMA is clarifying its regulatory approach to vaccine variations that might become necessary to ensure that effective vaccines continue to be available, not only for Europeans, but for people around the world who are suffering as a result of the COVID-19 pandemic.

More information

European Medicines Agency

Publicaciones relacionadas:

Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines Commission lists key steps for effective vaccination strategies and vaccines deployment EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen European Medicines Agency (EMA) gives go-ahead for use of anticovid tablet The European Commission will address the issue of Coronavirus at its meeting on 5th March

“This is a space for debate. All comments, for or against publication, that are respectful and do not contain expressions that are discriminatory, defamatory or contrary to current legislation will be published”.

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Publicaciones relacionadas

Global regulators discuss data requirements for phase 3 trials of COVID-19 vaccines Commission lists key steps for effective vaccination strategies and vaccines deployment EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen European Medicines Agency (EMA) gives go-ahead for use of anticovid tablet The European Commission will address the issue of Coronavirus at its meeting on 5th March

Footer

Centro de Documentación Europea de Almería
CDE Almería

Edificio Parque Científico-Tecnológico (Pita) Planta: 1ª, Despacho: 29
04120 – Ctra. Sacramento s/n.
Almería (Spain)
Teléfono: (+34) 950 015266

Sing in!

Navigation

  • HOME
  • WHAT´S ON
    • EU BULLETINS
    • EU NEWS
    • Activities
    • EU Calls and Awards
    • Radio Program «Europe with You»
  • DOCUMENTATION
    • Bibliographic Collection
      • Almería EDC Digital Collection
      • UNIVERSITY OF ALMERIA LIBRARY
    • Documentation by topic
    • EU Media Collection
      • Web Space
      • MEDIATHEQUE REPOSITORY
  • Europe on the net
    • Institutions
    • EU Representation in Spain
    • European information network of Andalusia
    • EU official journal
  • ABOUT US
    • Presentation
    • People
    • Contact

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Copyright © 2022 CDE Almería · Legal terms · Privacy policy · Cookies policy